Masters Speciality Pharma and hameln pharma plus are pleased to announce the signing of a new partnership agreement. The agreement, signed today 22nd March 2018, concerns the exclusive distribution of hameln pharma plus’ products in the Caribbean and further develops Masters’ goal of providing high quality medicines for all by prioritising emerging markets.
Masters and hameln pharma plus have a long-lasting relationship, spanning over 20 years. This new agreement expands the collaboration between the two companies, and builds on a previous partnership that enables the local registration and distribution of hameln products in Central America. Extending the existing partnership to the Caribbean allows the two companies to accelerate patients’ access to treatments in a wide range of therapeutic areas including hospital products and those for pain relief.
Wiltrud Beckerman, Vice President of Sales and Marketing at hameln pharma plus commented:
“hameln Pharmaceuticals UK and Masters Speciality Pharma have had a long standing trading relationship which has naturally extended to association with hameln Pharma Plus in August
2016. The first project, which focused on the registration of several hameln products in Central America resulted in a signed Distribution and Supply Agreement in January 2017.
Today we are very happy on both sides to sign our second Agreement, which covers the entire Caribbean region. Together, we will be able to serve many patients in parts of the world where hameln’s high-quality parenteral hospital products are desperately needed. We look forward to further intensifying the already successful cooperation, and are excited about our common achievements in the future.”
This latest partnership with hameln pharma plus is under Masters Speciality Pharma’s division, Masters Speciality Access (MSA) which aims to provide access to unlicensed medicines for emerging and developing markets.
hameln pharma plus is a pharmaceutical company that aims to serve the well-being of patients through its products, especially in urgent and life-saving situations. Our mission statement, “We are all patients” is the core of our business. We commit to operating with a clear focus on the patient and maintain close contact with our distributors and suppliers.
Masters Speciality Pharma was founded 35 years ago by Dr Zulf Masters and has a vision to provide access to high quality medicines for all, by prioritising emerging markets. It is headquartered in UK and has offices in the United States, El Salvador and Brazil. Masters operates with full regulatory oversight from MHRA, FDA, ENVISA and DNM and offers access to medicines in over 80 countries.